Rare Disease Landscape: Why You Need a Different Launch Playbook
In this video conversation with experts Kapil Raina, Chris Zealey, and Brian Williams, you’ll explore insights on successfully launching products in rare disease markets. We’ll cover key parameters for success and best practices for planning, timing, and budgeting specifically tailored for rare disease product launches.
Video Summary
Part 1: Why You Need a Different Launch Playbook
This video emphasizes the challenges and growth in the landscape of rare diseases, with about 7,000 identified but only 5% having treatments. This affects 30 million people in the US, including 16 million children, with 41% misdiagnosed and long diagnosis timelines.
Over half of recent drug approvals are for orphan drugs, leading to a growing revenue share despite the challenges of small patient populations and high costs. Most approvals utilize expedited pathways, increasing competition and pressuring companies to be first to market or demonstrate differentiation.
Other Rare Disease Resources:
Identify Rare Disease Product Launch Archetypes
Learn how to identify your rare disease product launch archetype to optimize your launch planning.
